Vascular Solutions Inc. (NASDAQ:VASC) shares hit a new 52-week high on Tuesday . The stock traded as high as $43.29 and last traded at $41.48, with a volume of 114,262 shares. The stock had previously closed at $42.40.

Several research analysts recently weighed in on the company. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $45.00 target price (up from $44.00) on shares of Vascular Solutions in a research report on Wednesday, April 27th. Zacks Investment Research raised Vascular Solutions from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a research report on Thursday, April 28th.

The company has a market cap of $723.33 million and a P/E ratio of 91.12. The company’s 50-day moving average is $39.39 and its 200-day moving average is $33.39.

Vascular Solutions (NASDAQ:VASC) last posted its quarterly earnings results on Monday, April 25th. The medical device company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.23 by $0.02. During the same period last year, the company earned $0.21 EPS. The business earned $39 million during the quarter, compared to analyst estimates of $38.37 million. The business’s revenue for the quarter was up 13.9% on a year-over-year basis. On average, equities research analysts anticipate that Vascular Solutions Inc. will post $1.21 EPS for the current fiscal year.

In related news, insider Timothy Slayton sold 2,994 shares of the stock in a transaction dated Wednesday, April 27th. The shares were sold at an average price of $36.72, for a total value of $109,939.68. Following the completion of the transaction, the insider now owns 9,787 shares of the company’s stock, valued at $359,378.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Howard Root sold 34,418 shares of the stock in a transaction dated Tuesday, May 24th. The stock was sold at an average price of $39.05, for a total transaction of $1,344,022.90. Following the completion of the transaction, the chief executive officer now directly owns 348,340 shares of the company’s stock, valued at approximately $13,602,677. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have bought and sold shares of the company. PNC Financial Services Group Inc. raised its position in Vascular Solutions by 10.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 108,609 shares of the medical device company’s stock valued at $3,735,000 after buying an additional 9,965 shares during the period. California State Teachers Retirement System boosted its stake in shares of Vascular Solutions by 1.3% in the fourth quarter. California State Teachers Retirement System now owns 31,944 shares of the medical device company’s stock valued at $1,099,000 after buying an additional 414 shares in the last quarter. Finally, Nationwide Fund Advisors boosted its stake in shares of Vascular Solutions by 0.5% in the fourth quarter. Nationwide Fund Advisors now owns 31,649 shares of the medical device company’s stock valued at $1,088,000 after buying an additional 153 shares in the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.